Targeted therapy of melanoma: Fact or fiction ?

Česká verzia

Authors: Švajdler M. Ihash2ihash4 ml. ^{1 2 1}
Authors place of work: Oddelenie patológie UNLP Košice, pracovisko Trieda SNP 1, Cytopathos s. r. o., Bratislava ¹
Published in the journal: Čes.-slov. Patol., 47, 2011, No. 4, p. 165-167
Category: Reviews Article

Summary

Advanced malignant melanoma is incurable by the current means of therapy. Traditional morphological classification (nodular melanoma, lentigo maligna melanoma, nevoid melanoma etc.) does not have any significant prognostic or predictive impact. Recent advances in molecular pathogenesis and the availability of targeted therapies have produced several positive results. In the near future, the main challenge for pathologists, geneticists and oncologists will be the identification of accurate therapeutic targets, as well as mechanisms of resistance, in melanoma in the particular patient in care.

Keywords:
melanoma – pathogenesis – genetics – targeted therapy – BRAF – vemurafenib

Zdroje

1. Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 2009; 27(6): 614–625.

2. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355(1): 51–65.

3. Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol 2011; 223(2): 241–250.

4. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353(20): 2135–2147.

5. Ko JM, Velez NF, Tsao H. Pathways to melanoma. Semin Cutan Med Surg 2010; 29(4): 210–217.

6. Settleman J. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. Cancer Cell 2009; 16(4): 278–279.

7. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS 2007; 115(10): 1161–1176.

8. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24(26): 4340–4346.

9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949–954.

10. Puxeddu J, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89(5): 2414–2420.

11. Puzanov I, Burnett P, Flaherty KT. Biological challenges of BRAF inhibitor therapy. Mol Oncol 2011; 5(2): 116–123.

12. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9): 809–819.

13. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive metastatic melanoma. J Clin Oncol 2011; 29(Suppl): 8509.

14. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507–2516.

15. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364(8): 772–774.